Literature DB >> 12841296

Management of Raynaud's phenomenon and digital ischemic lesions in scleroderma.

Laura K Hummers1, Fredrick M Wigley.   

Abstract

Raynaud's phenomenon is a challenging problem in patients who have scleroderma. It causes a great deal of morbidity with recurrent painful attacks and frequent digital ischemic lesions. The strategy to treat the vascular disease must consider treatment for the vasospasm and the intrinsic vascular disease with intimal proliferation and vessel occlusion. Vasodilator therapy remains the main method to treat Raynaud's phenomenon, but new understanding of the pathobiology of scleroderma vascular disease is providing novel treatment options. We need more investigations into these vasoactive drugs before routine use can be recommended. Critical ischemia can cause deep tissue injury and digital loss. An aggressive approach to reversing an ischemic crisis is essential for preventing these severe events.

Entities:  

Mesh:

Year:  2003        PMID: 12841296     DOI: 10.1016/s0889-857x(03)00019-x

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  16 in total

Review 1.  [Raynaud phenomenon in dermatology. Part 1: Pathophysiology and diagnostic approach].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-09       Impact factor: 0.751

Review 2.  [Raynaud phenomenon in dermatology : Part 2: therapy].

Authors:  C Sunderkötter; G Riemekasten
Journal:  Hautarzt       Date:  2006-10       Impact factor: 0.751

3.  Acute acalculous cholecystitis in systemic sclerosis.

Authors:  Takao Nagashima; Toshimi Imai; Kazuko Matsumoto; Sachiko Onishi; Shino Takatori; Masahiro Iwamoto; Seiji Minota
Journal:  Rheumatol Int       Date:  2009-10-23       Impact factor: 2.631

4.  Raynaud phenomenon that rapidly progressed to digital gangrene: a challenging diagnosis.

Authors:  Antonio G Tristano
Journal:  BMJ Case Rep       Date:  2009-06-04

5.  The Therapeutic Efficacy of Botulinum Toxin in Treating Scleroderma-Associated Raynaud's Phenomenon: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.

Authors:  Ricardo J Bello; Carisa M Cooney; Eitan Melamed; Keith Follmar; Gayane Yenokyan; Gwendolyn Leatherman; Ami A Shah; Fredrick M Wigley; Laura K Hummers; Scott D Lifchez
Journal:  Arthritis Rheumatol       Date:  2017-06-26       Impact factor: 10.995

Review 6.  My approach to the treatment of scleroderma.

Authors:  Ami A Shah; Fredrick M Wigley
Journal:  Mayo Clin Proc       Date:  2013-04       Impact factor: 7.616

Review 7.  Raynaud phenomenon in children.

Authors:  Ran D Goldman
Journal:  Can Fam Physician       Date:  2019-04       Impact factor: 3.275

8.  Paraneoplastic Raynaud's phenomenon in a breast cancer survivor.

Authors:  David Allen; David Robinson; Shikha Mittoo
Journal:  Rheumatol Int       Date:  2009-06-11       Impact factor: 2.631

9.  Digital ischemic loss in systemic sclerosis.

Authors:  Umaima Marvi; Lorinda Chung
Journal:  Int J Rheumatol       Date:  2010-08-24

10.  Management of cutaneous vascular complications in systemic scleroderma: experience from the German network.

Authors:  Ilka Herrgott; Gabriela Riemekasten; Nicolas Hunzelmann; Cord Sunderkötter
Journal:  Rheumatol Int       Date:  2008-03-05       Impact factor: 2.631

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.